Abstract
Aspirin is the key treatment in the secondary prevention of atherothrombosis. Interindividual variability of response has been linked to a higher risk for ischemic events. The aim of this study was to identify clinical and biologic factors predicting high on-aspirin platelet reactivity (HPR) in a high-risk, "real-world" population of vascular patients. All platelet testing performed from 2011 to 2013 in consecutive patients receiving long-term treatment with aspirin for coronary or cerebrovascular disease was retrospectively analyzed. Indications for platelet testing were recurrent ischemic events or high-risk angioplasty. HPR was defined as aggregation intensity≥20% using light-transmission aggregometry with arachidonic acid 0.5 mg/ml. Collagen-epinephrine platelet function analysis was also performed (threshold<165 seconds). Cardiovascular risk factors, usual biologic parameters, and antiplatelet treatment were recorded. A total of 1,508 patients were included (mean age 63 years, 71% men, 23% with diabetes). Antiplatelet treatment was aspirin alone in 333 patients and dual-antiplatelet therapy in 1,175 patients. HPR was found in 11.1% of patients. In multivariate analysis, independent predictive factors of HPR on light-transm...Continue Reading
References
Dec 1, 1985·Circulation·C PatronoL Forni
Mar 26, 2003·Journal of the American College of Cardiology·Patricia A GumEric J Topol
Feb 18, 2006·Circulation Research·Virgilio EvangelistaPaola Patrignani
Jun 16, 2007·European Heart Journal·Marie LordkipanidzéJean G Diodati
Apr 21, 2009·American Heart Journal·Thomas CuissetJean-Louis Bonnet
Oct 7, 2009·Thrombosis and Haemostasis·Ellen H A M ElsenbergChristian M Hackeng
Jun 8, 2010·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·Tobias GeislerMeinrad Gawaz
Aug 24, 2010·Atherosclerosis·Karin MüllerTobias Geisler
Oct 20, 2010·Journal of Thrombosis and Haemostasis : JTH·E L GroveS D Kristensen
Nov 9, 2011·Circulation·Glenn N LevineHenry H Ting
Jul 17, 2012·Thrombosis Research·Alf-Åge R PettersenIngebjørg Seljeflot
Oct 17, 2012·American Heart Journal·Jean-Guillaume DillingerPatrick Henry
Feb 15, 2013·Thrombosis and Haemostasis·S B LarsenA-M Hvas
Jun 7, 2013·Journal of Atherosclerosis and Thrombosis·Thomas GremmelSabine Steiner
Sep 27, 2013·European Heart Journal·Dániel AradiUNKNOWN Working Group on Thrombosis of the European Society of Cardiology
Oct 5, 2013·Blood·Fahumiya Samad, Wolfram Ruf
Citations
Jan 8, 2016·Journal of Thrombosis and Thrombolysis·Joonseok Kim, Richard C Becker
May 26, 2016·Resuscitation·Jean-François LlitjosJean-Guillaume Dillinger
Aug 18, 2016·European Heart Journal. Cardiovascular Pharmacotherapy·Stéphane Manzo-SilbermanPhilippe Gabriel Steg
Feb 15, 2019·Pediatric Blood & Cancer·Alexander A BoucherLori Luchtman-Jones
Nov 13, 2018·American Journal of Therapeutics·Elena BobescuLuigi G Marceanu
Feb 23, 2018·Annals of Intensive Care·Florian PrüllerDirk von Lewinski
May 9, 2019·Journal of Thrombosis and Thrombolysis·Monica VerdoiaUNKNOWN Novara Atherosclerosis Study Group (NAS)
Jul 11, 2018·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Jeffrey S Berger
Oct 12, 2018·Journal of Veterinary Pharmacology and Therapeutics·Jillian M HainesMichael H Court